Infectious Diseases News and Research RSS Feed - Infectious Diseases News and Research

Challenges involved in tracing the source of Legionnaires’ disease outbreak

Challenges involved in tracing the source of Legionnaires’ disease outbreak

Genetic research helps to explain why tracing the source of an outbreak of Legionnaires' disease that claimed four lives has proven to be more complicated than scientists hoped. [More]
Researchers use new gene editing tool to cut HIV DNA

Researchers use new gene editing tool to cut HIV DNA

The virus that causes AIDS is an efficient and crafty retrovirus. Once HIV inserts its DNA into the genome of its host cells, it has a long incubation period, and can remain dormant and hidden for years. [More]
Research opens door to potential drug target for deadly Ebola virus

Research opens door to potential drug target for deadly Ebola virus

Opening the door to potential treatments for the deadly Ebola virus, scientists have found that a protein made by the virus plays a role similar to that of a coat-check attendant. [More]
Vanderbilt researchers join multi-center effort to accelerate development of potential Ebola therapy

Vanderbilt researchers join multi-center effort to accelerate development of potential Ebola therapy

Vanderbilt University researchers have joined a multi-center effort led by Pennsylvania-based Inovio Pharmaceuticals Inc. to accelerate development of potential antibody therapies against the often-lethal Ebola virus. [More]
Mobidiag announces CE-IVD marking and launching of Amplidiag C. difficile+027 test

Mobidiag announces CE-IVD marking and launching of Amplidiag C. difficile+027 test

Mobidiag Ltd, a Finnish molecular diagnostics company specialized in the development of innovative diagnostics solutions for infectious diseases, today announced the launch of Amplidiag C. difficile+027, a qualitative qPCR-based test performed from DNA extracted from stool in suspected cases of C. difficile infection (CDI). [More]
Phase 1 clinical trial: Anti-HIV antibody significantly decreases HIV levels

Phase 1 clinical trial: Anti-HIV antibody significantly decreases HIV levels

A single infusion of an experimental anti-HIV antibody called 3BNC117 resulted in significantly decreased HIV levels that persisted for as long as 28 days in HIV-infected individuals, according to Phase 1 clinical trial findings published online today in Nature. [More]
New simeprevir clinical data to be presented at EASL's International Liver Congress 2015

New simeprevir clinical data to be presented at EASL's International Liver Congress 2015

Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, today announced that clinical data for simeprevir, its NS3/4A protease inhibitor for the treatment of hepatitis C virus (HCV) infection, will be presented at The International Liver Congress 2015 of the European Association for the Study of the Liver taking place in Vienna from April 22-26. [More]
Researchers reveal molecular structure of cytotoxin from Mycoplasma pneumoniae

Researchers reveal molecular structure of cytotoxin from Mycoplasma pneumoniae

Researchers from the School of Medicine at The University of Texas Health Science Center at San Antonio today revealed the molecular structure of the cytotoxin from Mycoplasma pneumoniae, a widespread, highly contagious bacterium that infects the lungs. [More]
New study could point to potential ways to address defects in learning, memory

New study could point to potential ways to address defects in learning, memory

Just as some people seem built to run marathons and have an easier time going for miles without tiring, others are born with a knack for memorizing things, from times tables to trivia facts. These two skills—running and memorizing—are not so different as it turns out. [More]
Study identifies gut immune system as new, effective target for diabetes

Study identifies gut immune system as new, effective target for diabetes

A commonly-used drug to treat inflammatory bowel disease, such as Crohn's disease, has been shown to lower blood sugar levels in obese mice, potentially identifying the gut immune system as a new and effective target in treating diabetes in humans. [More]
Scientists identify rhinovirus C receptor associated with severe asthma attacks

Scientists identify rhinovirus C receptor associated with severe asthma attacks

Scientists funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have identified a cellular receptor for rhinovirus C, a cold-causing virus that is strongly associated with severe asthma attacks. [More]

Babies with clinically suspected serious infections can be safely and effectively treated outside hospital

About 1 in 5 babies worldwide develop severe bacterial infections during the first month of life. These infections are responsible for around 700000 deaths in newborns every year... [More]
Findings of Ariosa's non-invasive prenatal testing study published online in NEJM

Findings of Ariosa's non-invasive prenatal testing study published online in NEJM

Results from the largest clinical trial to date, comparing non-invasive prenatal testing (NIPT) using the Harmony Prenatal Test with conventional first trimester combined screening (FTS) in a general pregnancy population have been published online in The New England Journal of Medicine. [More]
CHLA infectious diseases specialist discusses how parents can prevent measles outbreak

CHLA infectious diseases specialist discusses how parents can prevent measles outbreak

Since December, there have been more than 130 confirmed cases of measles in the state of California, most of them connected to an outbreak that originated in a Southern California amusement park. Many of the infected persons were not vaccinated against the extremely contagious virus, which manifests itself through rash, fever and coughing. [More]
Astellas Pharma, MD Anderson sign option agreement to research and develop new treatment for AML

Astellas Pharma, MD Anderson sign option agreement to research and develop new treatment for AML

Astellas Pharma Inc. and The University of Texas MD Anderson Cancer Center today announced the signing of an option agreement to research and develop a new treatment for patients with acute myeloid leukemia (AML). [More]
Novel biosensing platform could remotely determine treatment options for HIV, E-coli

Novel biosensing platform could remotely determine treatment options for HIV, E-coli

In much the same way that glucometers and pregnancy tests have revolutionized in-home diagnostic testing, researchers from Florida Atlantic University and collaborators have identified a new biosensing platform that could be used to remotely detect and determine treatment options for HIV, E-coli, Staphylococcus aureas and other bacteria. [More]
MRSA bacteria exposed to cigarette smoke become more resistant to antimicrobial peptides

MRSA bacteria exposed to cigarette smoke become more resistant to antimicrobial peptides

Methicillin-resistant Staphylococcus aureus (MRSA), an antibiotic-resistant superbug, can cause life-threatening skin, bloodstream and surgical site infections or pneumonia. Researchers at the University of California, San Diego School of Medicine now report that cigarette smoke may make matters worse. [More]
LA BioMed scientist awarded $80,000 to study effectiveness of pulmonary rehab in treating COPD

LA BioMed scientist awarded $80,000 to study effectiveness of pulmonary rehab in treating COPD

The ATS Foundation and Breathe California of Los Angeles have awarded $80,000 to Harry Rossiter, PhD, a lead researcher at the Los Angeles Biomedical Research Institute, to study the effectiveness of pulmonary rehabilitation in reducing chronic obstructive pulmonary disease (COPD) symptoms in an underserved population in Los Angeles. [More]
Purdue researchers identify new class of chemical insecticides to control mosquitoes

Purdue researchers identify new class of chemical insecticides to control mosquitoes

Purdue researchers have identified a new class of chemical insecticides that could provide a safer, more selective means of controlling mosquitoes that transmit key infectious diseases such as dengue, yellow fever and elephantiasis. [More]
Canada's VSV-EBOV Ebola vaccine proves safe, effective in Phase 1 clinical trial

Canada's VSV-EBOV Ebola vaccine proves safe, effective in Phase 1 clinical trial

The Honourable Rona Ambrose, Minister of Health, and Canada's Chief Public Health Officer, Dr. Gregory Taylor, today welcomed the news of promising trial outcomes of Canada's VSV-EBOV Ebola vaccine. The results of several studies and trials bring the world closer to ending this global outbreak through the provision of a commercially available vaccine. [More]
Advertisement
Advertisement